Dr. Emmanuel Antonarakis is the Clark Endowed Professor of Medicine and Director of Genitourinary Oncology in the Division of Hematology/Oncology and Transplantation at the University of Minnesota. He also serves as the Associate Director of Translational Research at the Masonic Cancer Center. His research focuses on clinical and translational studies in advanced prostate cancer as well as biomarker development. His seminal scientific contribution was the validation and clinical qualification of the AR-V7 biomarker in patients with castration-resistant prostate cancer. AR-V7 is an abnormal mRNA splicing variant of the androgen receptor which lacks the androgen-binding domain yet remains constitutively active as a transcription factor. Patients with detectable AR-V7 in their circulating tumor cells or tumor biopsies are generally resistant to further endocrine therapies but remain sensitive to chemotherapies. This test is now being used as a treatment-selection biomarker in the clinic to inform therapeutic choices for men with castration-resistant prostate cancer. He has also made other contributions to the understanding of hormonal resistance in prostate cancer, focusing on both AR-dependent and AR-independent mechanisms of escape. More recently, Dr. Antonarakis has developed an interest in understanding the role of germline and somatic DNA-repair alterations and their prognostic and therapeutic implications in patients with advanced prostate cancer. He is developing assays to detect DNA-repair deficiency in order to better select patients for treatment with synthetic-lethal approaches such as poly (ADP‐ribose) polymerase inhibitors and other strategies. He is leading several prospective clinical trials testing novel therapies in DNA-repair deficient advanced prostate cancer.